データなし
データなし
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
H.C. WainwrightはMedicenna Therapeutics(MDNAF.US)のレーティングを強気に据え置き、目標株価を2.5ドルに据え置いた
H.C. WainwrightのアナリストSwayampakula Ramakanthは$Medicenna Therapeutics(MDNAF.US)$のレーティングを強気に据え置き、目標株価を2.5ドルに据え置いた。TipRanksのデータによると、このアナリストの最近1年間の的中率は35.9%、平均リターンは4.4%である。注 TipRanksは、金融アナリストの分析データと、アナリストの
Updated MDNA11 Monotherapy and Combination Clinical Data From the Ongoing Phase 1/2 ABILITY-1 Study to Be Presented at the 2024 Immunotherapy Bridge Conference
Medicenna Therapeutics GAAP EPS of -C$0.05
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
Medicenna Announces Positive Single-Agent Activity of MDNA11 From Dose Expansion Cohort and Encouraging Safety Profile in Combination With KEYTRUDA (Pembrolizumab) at the 39th Annual Meeting of SITC